We came across a bullish thesis on Stepan Company on Danny’s Substack’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on SCL. Stepan Company’s share was trading at $66.46 as of February 17th. SCL’s trailing and forward P/E were 33.73 and 19.01 respectively according to Yahoo Finance.
Syda Productions/Shutterstock.com
Stepan Company operates across diversified chemical end markets, including surfactants, polyols, and specialty additives, which helps blunt the impact of single-point shocks from commodity or energy price swings. While macro factors like petrochemical feedstock costs and industrial demand cycles matter, the company’s diversified end markets—auto, construction, agrochemicals, and consumer—provide resilience.
Q3 2025 results illustrated this dynamic: consolidated net sales reached approximately $590.3 million, with global volumes rising ~1% year-over-year. Adjusted EBITDA grew ~6% to $56.2 million, and cash from operations totaled $69.8 million, generating free cash flow of ~$40.2 million, highlighting near-term cash generation despite mixed margin pressures. GAAP net income, however, fell sharply by 54% to $10.8 million, driven by higher interest, taxes, and an $8.6 million pre-tax drag from the Pasadena, TX alkoxylation start-up. Segment performance was mixed—Polymers & Specialty showed strength, while Surfactants faced feedstock inflation and start-up effects.
Management remains pragmatic and transparent, emphasizing start-up costs, feedstock pressures, and ongoing capital allocation, including continued dividends. Key operational risk centers on the Pasadena commissioning; execution issues or cost overruns could materially impact margins. Additional downside stems from sustained commodity spikes or major volume declines in industrial end markets. Upside catalysts include successful Pasadena ramp, feedstock stabilization, continued Polymers strength, positive EBITDA surprises, or special dividends funded by free cash flow.
Valuation is attractive relative to normalized EBITDA, with steady cash conversion providing downside protection. For investors, Stepan represents a core cyclical industrial allocation, with prudent portfolio sizing of 1–3% conservatively and 3–6% for active positioning, conditional on near-term operational de-risking and feedstock easing. The market is positioned to reward operational execution and normalized margins.
Previously, we covered a bullish thesis on Eastman Chemical Company (EMN) by Necessary-Damage5658 in November 2024, which highlighted its regulatory compliance advantage and ability to capture market share from restricted competitors. EMN’s stock price has depreciated by approximately 21.73% since our coverage. Danny Green shares a similar view but emphasizes Stepan Company’s diversified end markets, resilience to commodity cycles, and strong near-term cash flow.
Stepan Company is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 18 hedge fund portfolios held SCL at the end of the third quarter which was 15 in the previous quarter. While we acknowledge the risk and potential of SCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SCL and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
Disclosure: None.
